Team develops first 3D look at interaction between immune sensor and protein that helps bacteria move
LA JOLLA, Calif., February 16, 2012 – To invade organisms such as humans, bacteria make use of a protein called flagellin, part of a tail-like appendage that helps the bacteria move about. Now, for the first time, a team led by scientists at The Scripps Research Institute and Sanford-Burnham Medical Research Institute has determined the 3D structure of the interaction between this critical bacterial protein and an immune molecule called TLR5, shedding light on how the body protects itself from such foreign invaders.
The study, published February 17 in Science, not only helps decipher the molecular mechanism underlying TLR5 recognition and function, but it also advances knowledge that’s key to the design of new therapeutics.
“The structure of the TLR5-flagellin complex visualizes molecular events that occur on the cell surface to trigger flagellin-induced host immune responses, and provides significant insights into the structural basis for TLR5 recognition and signaling,” said Ian Wilson, D.Sc., Hansen Professor of Structural Biology at Scripps Research who led the study with Andrei Osterman, Ph.D., professor in Sanford-Burnham’s Infectious and Inflammatory Disease Center.
“Gaining knowledge of a molecular interaction and action—as we did in this study— is critically important to the further development of therapeutics based on agonists and antagonists of the TLR5 receptor,” said Osterman.
Flagellin is a component in some vaccines and a derivative of this protein is currently being developed as a medical countermeasure to radiation by Cleveland BioLabs, Inc. (NASDAQ:CBLI), also a contributor to the new study.
Keeping an eye out for infection
Some of the body’s first lines of defense against invading bacteria are Toll-like receptors (TLRs), sensors that sit on the surface of many different types of cells. There are roughly a dozen different TLRs, each keeping an eye out for a particular sign of infection.
TLR5, for example, specifically recognizes and binds to flagellin. Like most TLRs, TLR5 does more than just sense bacteria—it also sends signals that call up immune cells to destroy the intruder. But to fully understand how TLR5 works, scientists needed to be able to see its 3D shape and how it binds to flagellin.
The structures of several other TLRs had already been solved, but each of these binds non-protein molecules, such as RNA or lipids. For technical reasons, determining the structure of TLR5—the only TLR that binds a protein—had long been a challenge.
In this study, the Scripps Research team was able to overcome these hurdles using TLR5 found in zebrafish as a proxy for the human protein. The scientists were then able to apply a technique called X-ray crystallography, which uses powerful X-ray beams to produce 3D images of proteins at the atomic level.
At Sanford-Burnham, Osterman and his team used biochemical and protein engineering methods to unravel the mechanistic details of interactions between TLR5 and flagellin and its derivatives.
Scientists at Roswell Park Cancer Institute and Cleveland BioLabs, Inc. in Buffalo, under the leadership of Andrei Gudkov, Ph.D., performed complementary experiments in human cells expressing TLR5 and validated the fish TLR5 as a good surrogate for human TLR5.
This research was funded by the National Institute of Allergy and Infectious Diseases, the Skaggs Institute for Chemical Biology at Scripps Research, and Cleveland BioLabs, Inc. In addition to Wilson, Osterman, and Gudkov, the study’s co-authors include Sung-il Yoon, Scripps Research; Oleg Kurnasov, Sanford-Burnham; Venkatesh Natarajan, Roswell Park Cancer Institute; and Minsun Hong, Scripps Research.
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. The Institute consistently ranks among the top five organizations worldwide for its scientific impact in the fields of biology and biochemistry (defined by citations per publication) and currently ranks third in the nation in NIH funding among all laboratory-based research institutes. Sanford-Burnham is a highly innovative organization, currently ranking second nationally among all organizations in capital efficiency of generating patents, defined by the number of patents issued per grant dollars awarded, according to government statistics.
Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a U.S.-based, non-profit public benefit corporation, with operations in San Diego (La Jolla), Santa Barbara, and Orlando (Lake Nona). For more information, please visit our website (www.sanfordburnham.org) or blog (http://beaker.sanfordburnham.org). You can also receive updates by following us on Facebook and Twitter.
# # #
Office of Communications